EXEL : Analysis & Opinions

  1. Genentech Withdraws Cost Claims Against Exelixis

    January 10, 2017
    Exelixis stock was buoyed after its drug partner agreed to stop charging it for certain expenses.
  2. Pfizer's Kidney Drug Faces a New Rival (EXEL, PFE)

    October 11, 2016
    Pfizer finds new indications for using its kidney cancer drug, Sutent, as it faces imminent competition from Exelixis's treatment,
  3. Exelixis Finds Success with Cabozantinib (EXEL)

    October 10, 2016
    Successful results from Phase II to treat advanced renal cell carcinoma (RCC) cases could expand Exelixis' patient population, ...
  4. Exelixis Reports Genitourinary Results (EXEL)

    October 7, 2016
    Company’s success with combination of cabozantinib and nivolumab in early stage trials paves way for progress.
  5. Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL)

    September 14, 2016
    The much-anticipated approval from the European Union will add a new stream of revenue for the monopoly drug.
  6. Exelixis Shares Soar on Cancer Therapies (EXEL)

    September 13, 2016
    Two recent drug launches, continued success in trials, and rising revenues are fueling Exelixis's share price.
  7. The Top 5 Small-Cap Biotechnology Stocks for 2016

    December 14, 2015
    Discover the top five small-cap biotechnology stocks for 2016, with a summary, growth outlook and expected price target for ...
  8. Make Room for Exelixis in Your Portfolio

    August 12, 2015
    Discover information and analysis on the biopharmaceutical company, Exelixis, and learn what makes it a good stock to consider ...
  9. ASCO Reaffirms Why I'm Holding Exelixis

    June 5, 2015
    There are dozens upon dozens of healthcare events each and every year that highlight the latest advancements in pharmaceuticals, ...
  10. 5 Things Exelixis Management Wants You to Know

    May 22, 2015
    Just a few weeks ago, highly followed small-cap biotech stock Exelixis (NASDAQ: EXEL) reported its first-quarter earnings ...
  11. How 42 Words Completely Changed Exelixis' Report

    May 4, 2015
    Exelixis (NASDAQ: EXEL), a predominantly clinical-stage biopharmaceutical company focused on developing novel therapies ...
  12. 3 (Rough) Dates Exelixis Shareholders Need to Know

    March 30, 2015
    EXEL data by YCharts. It's incredible what a difference the simple tick of a calendar can bring for shareholders in Exelixis ...